Financial Projections - The estimated net profit for 2024 is projected to be between 32 million and 41 million CNY, representing a decline of 54.14% to 64.21% compared to the previous year's profit of 89.40 million CNY [3]. - The estimated operating revenue for 2024 is expected to be between 400 million and 460 million CNY, reflecting a year-on-year decrease of 15.26% to 26.31% [5]. - The estimated net profit after deducting non-recurring gains and losses is projected to be between 24 million and 31 million CNY, down 51.34% to 62.33% from 63.70 million CNY in the previous year [3]. - The impact of non-recurring gains and losses on net profit for 2024 is expected to be approximately 9.56 million CNY, compared to 25.70 million CNY in the same period last year [7]. Cost Management and Efficiency - The company has implemented multiple cost-reduction and efficiency-enhancement measures to mitigate the impact of market factors and industry procurement policies [5]. - The comprehensive gross profit margin is expected to remain stable, with both operating expenses and expense ratios declining year-on-year [6]. Impairment Losses - The company has recognized significant credit impairment losses and asset impairment losses during the reporting period, which have substantially increased compared to the previous year [6]. Profitability Impact - The overall profitability of the company's equity investees and industry investment funds has significantly declined, adversely affecting the net profit attributable to shareholders [6]. Financial Reporting - The financial data in the earnings forecast is based on preliminary estimates by the company's finance department and has not been audited by the accounting firm [4]. - The detailed operating performance for 2024 will be disclosed in the company's annual report, and investors are advised to make cautious decisions [7].
透景生命(300642) - 2024 Q4 - 年度业绩预告